The preliminary results from Regeneron's CHORD trial are positive, showing that its otoferlin gene therapy (DB-OTO) improves auditory responses in a child with profound genetic hearing loss. This could potentially boost the company's reputation in the field of genetic medicines for hearing loss, and may lead to increased investor interest in the company. However, as these are preliminary results, further trials and regulatory approvals are needed before the therapy can be marketed.